Bayer and Asklepios BioPharmaceutical (AskBio), a wholly-owned and independently operated subsidiary of Bayer, presented results from the 18-month Phase Ib clinical trial for AB-1005, an investigational gene therapy for the treatment of patients with Parkinson's disease (PD).

The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA.

AB-1005 was well tolerated with no serious side effects attributed in all 11 patients at 18 months, meeting the primary endpoint.

Based on the safety and efficacy results presented, a Phase II trial (REGENERATE PD) has been developed and is expected to begin enrolling in the US, EU and UK later this year.

'These initial results are encouraging and demonstrate that AB-1005 is well tolerated in this study in patients with mild to moderate Parkinson's disease,' said Krystof Bankiewicz, MD, PhD, Scientific President, Parkinson's Disease and MSA, AskBio.

"In addition, they highlight areas of potential future exploration in our upcoming Phase II REGENERATE PD study, which will further investigate the potential efficacy of AB-1005 in the treatment of Parkinson's disease."

Copyright (c) 2024 All rights reserved.